Promimic
26.5
SEK
-19.7 %
PRO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-19.7%
-26.18%
-25.35%
-33.75%
+2.71%
-18.96%
-24.29%
-
-
+62.76%
promimic.com
Promimic specializes in biotechnology. The company conducts research and development in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The main operations are in Europe and America, where research and development are conducted in-house but also through partners.
Revenue
37.07M
EBIT %
-24.6 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PRO
Daily low / high price
25.5 / 31.1
SEK
Market cap
500.65M SEK
Turnover
644.67K SEK
Volume
23K
Financial calendar
Interim report
2024-11-21
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| K-Svets Venture AB | 38.7 % | 38.7 % |
| KDev Investments AB | 12.5 % | 12.5 % |
| Chalmers Ventures AB | 6.6 % | 6.6 % |
| Riepen LLC | 5.6 % | 5.6 % |
| Andra AP-fonden | 5.1 % | 5.1 % |
| Swedbank Robur Ny Teknik | 3.3 % | 3.3 % |
| Avanza | 3.1 % | 3.1 % |
| Firma Andersson och Kjellin AB | 2.3 % | 2.3 % |
| Martin Andersson | 2.0 % | 2.0 % |
| Per Kjellin | 2.0 % | 2.0 % |
ShowingAll content types
Valberedning utsedd i Promimic AB (publ)
Promimic AB: Promimic har löst in optionsprogrammet 2021-TO3
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools